These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23590726)

  • 21. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
    Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A
    Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577
    [No Abstract]   [Full Text] [Related]  

  • 22. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
    J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vocal cord paralysis secondary to vincristine].
    Nafil H; Tazi I; Mahmal L
    Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
    Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.
    Wilcox RA
    Lancet Haematol; 2018 May; 5(5):e182-e183. PubMed ID: 29703333
    [No Abstract]   [Full Text] [Related]  

  • 26. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
    Kim JG; Sohn SK; Chae YS; Kim DH; Baek JH; Lee KB; Lee JJ; Chung IJ; Kim HJ; Yang DH; Lee WS; Joo YD; Sohn CH
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):35-9. PubMed ID: 16308699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Picture in clinical hematology].
    Hatsuse M; Shimazaki C; Yumiba T
    Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
    [No Abstract]   [Full Text] [Related]  

  • 28. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
    Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
    Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
    [No Abstract]   [Full Text] [Related]  

  • 29. [A case report of composite lymphoma].
    Wu J; Wang ZC; Chen XD
    Ai Zheng; 2007 Apr; 26(4):447. PubMed ID: 17430672
    [No Abstract]   [Full Text] [Related]  

  • 30. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
    Quesada AE; Rios A; Brown RE; Nguyen ND
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
    [No Abstract]   [Full Text] [Related]  

  • 33. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
    Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
    Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumor lysis in a patient with peripheral T-cell lymphoma unspecified.
    Hirata Y; Yokote T; Kobayashi K; Nakayama S; Miyoshi T; Akioka T; Tsuji M; Takubo T; Hanafusa T
    Leuk Lymphoma; 2009 Jul; 50(7):1226-9. PubMed ID: 19557646
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
    Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
    Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
    Gallamini A; Zaja F; Patti C; Billio A; Specchia MR; Tucci A; Levis A; Manna A; Secondo V; Rigacci L; Pinto A; Iannitto E; Zoli V; Torchio P; Pileri S; Tarella C
    Blood; 2007 Oct; 110(7):2316-23. PubMed ID: 17581918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Necrotizing leukoencephalopathy following CHOP chemotherapy.
    Blaes AH; Santa-Cruz KS; Lee CK; Hui SK; Peterson BA
    Leuk Res; 2008 Oct; 32(10):1611-4. PubMed ID: 18378307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment strategy of high malignancy non-Hodgkin lymphomas].
    Pfreundschuh M; Trümper L
    Praxis (Bern 1994); 1998 Jun; 87(23):812-5. PubMed ID: 9654988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.